West Syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. As per DelveInsight, in 2020, the total West Syndrome diagnosed prevalent population was 8,601 in the seven major markets (i.e the USA, EU5, and Japan). The West Syndrome Market Size in 7MM was found to be USD 182.4 Million in 2020.
Some of the key factors such as clinical development activities, product innovations, and technological advancements, support from various organizations, and the rising prevalence of infantile spasms are expected to drive the West Syndrome Market Growth in the coming years. However, the factor such as delayed diagnosis and treatment, serious side effects of medications, lack of prevalence-based studies for infantile spasms, challenges in conducting clinical trials for rare diseases and lack of late phase clinical studies will hamper the market growth.
Globally, some of the key companies in the West Syndrome Market involve INSYS Therapeutics, GW Pharmaceuticals, BioPharm Solutions, and several others.
For more details, visit: West Syndrome Market Growth